SMG1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1888452	0.73	8/20
SCHEMBL1631108	0.70	8/20
SCHEMBL1889414	0.52	8/20
SCHEMBL3083714	0.45	8/20
SCHEMBL827571	0.66	7/20
SCHEMBL1667404	0.62	7/20
SCHEMBL3130169	0.59	7/20
SCHEMBL434180	0.57	7/20
SCHEMBL2877271	0.55	7/20
SCHEMBL2375211	0.51	7/20
SCHEMBL1035051	0.44	7/20
SCHEMBL1633189	0.50	6/20
SCHEMBL2228483	0.49	6/20
SCHEMBL3254956	0.49	6/20
SCHEMBL1633017	0.72	5/20
SCHEMBL1631045	0.59	5/20
SCHEMBL2545044	0.54	5/20
SCHEMBL2542328	0.54	5/20
SCHEMBL2545759	0.54	5/20
SCHEMBL2539352	0.53	5/20

Clinical trials — most relevant to SMG1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule	PHASE2	NOT_YET_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers	PHASE1	RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia	nan	RECRUITING
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Precision Diagnosis and Therapy for Rare Diseases by Interpreting Non-coding Genomes	nan	RECRUITING
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Maternal Genes and Epimutations: Beckwith-Wiedemann Syndrome & Reproductive Risks	nan	RECRUITING
miRNA as a Growth Plate Marker After GH	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SMG1 binder may also engage these)

Protein	Name	Similarity
Q8BKX6	—	1.000	Q8BKX6 →
C5J7W8	—	1.000	C5J7W8 →
P97313	—	1.000	P97313 →
Q9DEI1	—	1.000	Q9DEI1 →
Q9SXA1	—	1.000	Q9SXA1 →
Q0VF22	—	1.000	Q0VF22 →
E1C231	—	1.000	E1C231 →
Q5MNV8	—	1.000	Q5MNV8 →
PI4KA	Phosphatidylinositol 4-kinase alpha	1.000	landscape →
F4I893	—	1.000	F4I893 →
O02811	—	1.000	O02811 →
F4IGA5	—	1.000	F4IGA5 →
Q95JJ5	—	1.000	Q95JJ5 →
Q6CAD2	—	1.000	Q6CAD2 →
O08662	—	1.000	O08662 →
P42173	—	1.000	P42173 →
A1Z8X3	—	0.999	A1Z8X3 →
Q9JKK8	—	0.999	Q9JKK8 →
O74447	—	0.999	O74447 →
P32333	—	0.999	P32333 →
O14715	—	0.999	O14715 →
Q80UK8	—	0.999	Q80UK8 →
E9Q3L2	—	0.998	E9Q3L2 →
A2A6H3	—	0.998	A2A6H3 →
Q18892	—	0.998	Q18892 →
Q5EB59	—	0.998	Q5EB59 →
Q99666	—	0.998	Q99666 →
Q9DE14	—	0.998	Q9DE14 →
Q6P423	—	0.997	Q6P423 →
E9Q555	—	0.997	E9Q555 →